Soleno withdraws EU marketing application for VIOKAT (PWS hyperphagia)

SOLENO THERAPEUTICS INC

Voluntarily withdrew MAA for VIOKAT (diazoxide choline) from EMA for Prader-Willi syndrome hyperphagia.
Decision based on business and strategic considerations; company may re-engage with regulators later.
VIOKAT is marketed in the US as VYKAT XR for adults and children aged 4+ with PWS.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.